 | • レポートコード：MRC2-11QY03645 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は癌血管新生阻害剤のグローバル市場について調査・分析したレポートです。種類別（VEGF標的療法、FGF標的療法、癌遺伝子標的療法、マトリックス分解・リモデリング標的療法、その他）市場規模、用途別（がん、インターフェロンアルファ-2α、眼血管新生）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別癌血管新生阻害剤の競争状況、市場シェア ・世界の癌血管新生阻害剤市場：種類別市場規模 2015年-2020年（VEGF標的療法、FGF標的療法、癌遺伝子標的療法、マトリックス分解・リモデリング標的療法、その他） ・世界の癌血管新生阻害剤市場：種類別市場規模予測 2021年-2026年（VEGF標的療法、FGF標的療法、癌遺伝子標的療法、マトリックス分解・リモデリング標的療法、その他） ・世界の癌血管新生阻害剤市場：用途別市場規模 2015年-2020年（がん、インターフェロンアルファ-2α、眼血管新生） ・世界の癌血管新生阻害剤市場：用途別市場規模予測 2021年-2026年（がん、インターフェロンアルファ-2α、眼血管新生） ・北米の癌血管新生阻害剤市場分析：米国、カナダ ・ヨーロッパの癌血管新生阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの癌血管新生阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の癌血管新生阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの癌血管新生阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Intas Pharmaceuticals、Kyowa Hakko Kirin、Levolta Pharmaceuticals、Mabtech、Marsala Biotech、Neumedicines、Genentech、Five Prime Therapeutics、Fuji Film Kyowa Kirin Biologics、Genexine、Hetero Drugs、ImClone Systems、Novartis ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Cancer Angiogenesis Inhibitors Market
The global Cancer Angiogenesis Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Cancer Angiogenesis Inhibitors Scope and Market Size
Cancer Angiogenesis Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Angiogenesis Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cancer Angiogenesis Inhibitors market is segmented into
VEGF Targeted Therapy
FGF Targeted Therapies
Oncogene Targeted Therapy
Matrix Degrading & Remodeling Targeted Therapy
Others
Segment by Application, the Cancer Angiogenesis Inhibitors market is segmented into
Cancer
Interferon Alpha-2α
Ocular Neovascularization
Regional and Country-level Analysis
The Cancer Angiogenesis Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Angiogenesis Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Angiogenesis Inhibitors Market Share Analysis
Cancer Angiogenesis Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Angiogenesis Inhibitors business, the date to enter into the Cancer Angiogenesis Inhibitors market, Cancer Angiogenesis Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Intas Pharmaceuticals
Kyowa Hakko Kirin
Levolta Pharmaceuticals
Mabtech
Marsala Biotech
Neumedicines
Genentech
Five Prime Therapeutics
Fuji Film Kyowa Kirin Biologics
Genexine
Hetero Drugs
ImClone Systems
Novartis
1 Study Coverage
1.1 Cancer Angiogenesis Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Cancer Angiogenesis Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Type
1.4.2 VEGF Targeted Therapy
1.4.3 FGF Targeted Therapies
1.4.4 Oncogene Targeted Therapy
1.4.5 Matrix Degrading & Remodeling Targeted Therapy
1.4.6 Others
1.5 Market by Application
1.5.1 Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Application
1.5.2 Cancer
1.5.3 Interferon Alpha-2α
1.5.4 Ocular Neovascularization
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cancer Angiogenesis Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Cancer Angiogenesis Inhibitors Revenue 2015-2026
2.1.2 Global Cancer Angiogenesis Inhibitors Sales 2015-2026
2.2 Global Cancer Angiogenesis Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cancer Angiogenesis Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cancer Angiogenesis Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cancer Angiogenesis Inhibitors Competitor Landscape by Players
3.1 Cancer Angiogenesis Inhibitors Sales by Manufacturers
3.1.1 Cancer Angiogenesis Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Cancer Angiogenesis Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Cancer Angiogenesis Inhibitors Revenue by Manufacturers
3.2.1 Cancer Angiogenesis Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Cancer Angiogenesis Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cancer Angiogenesis Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cancer Angiogenesis Inhibitors Revenue in 2019
3.2.5 Global Cancer Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cancer Angiogenesis Inhibitors Price by Manufacturers
3.4 Cancer Angiogenesis Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Cancer Angiogenesis Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Angiogenesis Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Angiogenesis Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cancer Angiogenesis Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2015-2020)
4.1.2 Global Cancer Angiogenesis Inhibitors Revenue by Type (2015-2020)
4.1.3 Cancer Angiogenesis Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cancer Angiogenesis Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Cancer Angiogenesis Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Angiogenesis Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Cancer Angiogenesis Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cancer Angiogenesis Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cancer Angiogenesis Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2015-2020)
5.1.2 Global Cancer Angiogenesis Inhibitors Revenue by Application (2015-2020)
5.1.3 Cancer Angiogenesis Inhibitors Price by Application (2015-2020)
5.2 Cancer Angiogenesis Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Cancer Angiogenesis Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Angiogenesis Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Angiogenesis Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cancer Angiogenesis Inhibitors by Country
6.1.1 North America Cancer Angiogenesis Inhibitors Sales by Country
6.1.2 North America Cancer Angiogenesis Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cancer Angiogenesis Inhibitors Market Facts & Figures by Type
6.3 North America Cancer Angiogenesis Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe Cancer Angiogenesis Inhibitors by Country
7.1.1 Europe Cancer Angiogenesis Inhibitors Sales by Country
7.1.2 Europe Cancer Angiogenesis Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Angiogenesis Inhibitors Market Facts & Figures by Type
7.3 Europe Cancer Angiogenesis Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cancer Angiogenesis Inhibitors by Region
8.1.1 Asia Pacific Cancer Angiogenesis Inhibitors Sales by Region
8.1.2 Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cancer Angiogenesis Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Cancer Angiogenesis Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cancer Angiogenesis Inhibitors by Country
9.1.1 Latin America Cancer Angiogenesis Inhibitors Sales by Country
9.1.2 Latin America Cancer Angiogenesis Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cancer Angiogenesis Inhibitors Market Facts & Figures by Type
9.3 Central & South America Cancer Angiogenesis Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cancer Angiogenesis Inhibitors by Country
10.1.1 Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country
10.1.2 Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cancer Angiogenesis Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Cancer Angiogenesis Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Intas Pharmaceuticals
11.1.1 Intas Pharmaceuticals Corporation Information
11.1.2 Intas Pharmaceuticals Description and Business Overview
11.1.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Products Offered
11.1.5 Intas Pharmaceuticals Related Developments
11.2 Kyowa Hakko Kirin
11.2.1 Kyowa Hakko Kirin Corporation Information
11.2.2 Kyowa Hakko Kirin Description and Business Overview
11.2.3 Kyowa Hakko Kirin Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Products Offered
11.2.5 Kyowa Hakko Kirin Related Developments
11.3 Levolta Pharmaceuticals
11.3.1 Levolta Pharmaceuticals Corporation Information
11.3.2 Levolta Pharmaceuticals Description and Business Overview
11.3.3 Levolta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Products Offered
11.3.5 Levolta Pharmaceuticals Related Developments
11.4 Mabtech
11.4.1 Mabtech Corporation Information
11.4.2 Mabtech Description and Business Overview
11.4.3 Mabtech Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Mabtech Cancer Angiogenesis Inhibitors Products Offered
11.4.5 Mabtech Related Developments
11.5 Marsala Biotech
11.5.1 Marsala Biotech Corporation Information
11.5.2 Marsala Biotech Description and Business Overview
11.5.3 Marsala Biotech Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Marsala Biotech Cancer Angiogenesis Inhibitors Products Offered
11.5.5 Marsala Biotech Related Developments
11.6 Neumedicines
11.6.1 Neumedicines Corporation Information
11.6.2 Neumedicines Description and Business Overview
11.6.3 Neumedicines Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Neumedicines Cancer Angiogenesis Inhibitors Products Offered
11.6.5 Neumedicines Related Developments
11.7 Genentech
11.7.1 Genentech Corporation Information
11.7.2 Genentech Description and Business Overview
11.7.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Genentech Cancer Angiogenesis Inhibitors Products Offered
11.7.5 Genentech Related Developments
11.8 Five Prime Therapeutics
11.8.1 Five Prime Therapeutics Corporation Information
11.8.2 Five Prime Therapeutics Description and Business Overview
11.8.3 Five Prime Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Products Offered
11.8.5 Five Prime Therapeutics Related Developments
11.9 Fuji Film Kyowa Kirin Biologics
11.9.1 Fuji Film Kyowa Kirin Biologics Corporation Information
11.9.2 Fuji Film Kyowa Kirin Biologics Description and Business Overview
11.9.3 Fuji Film Kyowa Kirin Biologics Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Products Offered
11.9.5 Fuji Film Kyowa Kirin Biologics Related Developments
11.10 Genexine
11.10.1 Genexine Corporation Information
11.10.2 Genexine Description and Business Overview
11.10.3 Genexine Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Genexine Cancer Angiogenesis Inhibitors Products Offered
11.10.5 Genexine Related Developments
11.1 Intas Pharmaceuticals
11.1.1 Intas Pharmaceuticals Corporation Information
11.1.2 Intas Pharmaceuticals Description and Business Overview
11.1.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Products Offered
11.1.5 Intas Pharmaceuticals Related Developments
11.12 ImClone Systems
11.12.1 ImClone Systems Corporation Information
11.12.2 ImClone Systems Description and Business Overview
11.12.3 ImClone Systems Sales, Revenue and Gross Margin (2015-2020)
11.12.4 ImClone Systems Products Offered
11.12.5 ImClone Systems Related Developments
11.13 Novartis
11.13.1 Novartis Corporation Information
11.13.2 Novartis Description and Business Overview
11.13.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Novartis Products Offered
11.13.5 Novartis Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cancer Angiogenesis Inhibitors Market Estimates and Projections by Region
12.1.1 Global Cancer Angiogenesis Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Cancer Angiogenesis Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Cancer Angiogenesis Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Cancer Angiogenesis Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Cancer Angiogenesis Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Cancer Angiogenesis Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Cancer Angiogenesis Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Cancer Angiogenesis Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Cancer Angiogenesis Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Cancer Angiogenesis Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cancer Angiogenesis Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cancer Angiogenesis Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cancer Angiogenesis Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cancer Angiogenesis Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Cancer Angiogenesis Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Cancer Angiogenesis Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Cancer Angiogenesis Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Cancer Angiogenesis Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cancer Angiogenesis Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cancer Angiogenesis Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cancer Angiogenesis Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cancer Angiogenesis Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cancer Angiogenesis Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cancer Angiogenesis Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cancer Angiogenesis Inhibitors Market Segments
Table 2. Ranking of Global Top Cancer Angiogenesis Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of VEGF Targeted Therapy
Table 5. Major Manufacturers of FGF Targeted Therapies
Table 6. Major Manufacturers of Oncogene Targeted Therapy
Table 7. Major Manufacturers of Matrix Degrading & Remodeling Targeted Therapy
Table 8. Major Manufacturers of Others
Table 9. Global Cancer Angiogenesis Inhibitors Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Cancer Angiogenesis Inhibitors Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Cancer Angiogenesis Inhibitors Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Cancer Angiogenesis Inhibitors Sales Market Share by Regions (2015-2020)
Table 13. Global Cancer Angiogenesis Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Cancer Angiogenesis Inhibitors Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Cancer Angiogenesis Inhibitors Sales Share by Manufacturers (2015-2020)
Table 16. Global Cancer Angiogenesis Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Cancer Angiogenesis Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Angiogenesis Inhibitors as of 2019)
Table 18. Cancer Angiogenesis Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Cancer Angiogenesis Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Cancer Angiogenesis Inhibitors Price (2015-2020) (USD/Pcs)
Table 21. Cancer Angiogenesis Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Cancer Angiogenesis Inhibitors Product Type
Table 23. Date of International Manufacturers Enter into Cancer Angiogenesis Inhibitors Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 26. Global Cancer Angiogenesis Inhibitors Sales Share by Type (2015-2020)
Table 27. Global Cancer Angiogenesis Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Cancer Angiogenesis Inhibitors Revenue Share by Type (2015-2020)
Table 29. Cancer Angiogenesis Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 31. Global Cancer Angiogenesis Inhibitors Sales Share by Application (2015-2020)
Table 32. North America Cancer Angiogenesis Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 33. North America Cancer Angiogenesis Inhibitors Sales Market Share by Country (2015-2020)
Table 34. North America Cancer Angiogenesis Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2015-2020)
Table 36. North America Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 37. North America Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Table 38. North America Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 39. North America Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Table 40. Europe Cancer Angiogenesis Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Country (2015-2020)
Table 42. Europe Cancer Angiogenesis Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2015-2020)
Table 44. Europe Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Table 46. Europe Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Cancer Angiogenesis Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Table 56. Latin America Cancer Angiogenesis Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Cancer Angiogenesis Inhibitors Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Cancer Angiogenesis Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2015-2020)
Table 60. Latin America Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Table 62. Latin America Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Table 72. Intas Pharmaceuticals Corporation Information
Table 73. Intas Pharmaceuticals Description and Major Businesses
Table 74. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Intas Pharmaceuticals Product
Table 76. Intas Pharmaceuticals Recent Development
Table 77. Kyowa Hakko Kirin Corporation Information
Table 78. Kyowa Hakko Kirin Description and Major Businesses
Table 79. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Kyowa Hakko Kirin Product
Table 81. Kyowa Hakko Kirin Recent Development
Table 82. Levolta Pharmaceuticals Corporation Information
Table 83. Levolta Pharmaceuticals Description and Major Businesses
Table 84. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Levolta Pharmaceuticals Product
Table 86. Levolta Pharmaceuticals Recent Development
Table 87. Mabtech Corporation Information
Table 88. Mabtech Description and Major Businesses
Table 89. Mabtech Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Mabtech Product
Table 91. Mabtech Recent Development
Table 92. Marsala Biotech Corporation Information
Table 93. Marsala Biotech Description and Major Businesses
Table 94. Marsala Biotech Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Marsala Biotech Product
Table 96. Marsala Biotech Recent Development
Table 97. Neumedicines Corporation Information
Table 98. Neumedicines Description and Major Businesses
Table 99. Neumedicines Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Neumedicines Product
Table 101. Neumedicines Recent Development
Table 102. Genentech Corporation Information
Table 103. Genentech Description and Major Businesses
Table 104. Genentech Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Genentech Product
Table 106. Genentech Recent Development
Table 107. Five Prime Therapeutics Corporation Information
Table 108. Five Prime Therapeutics Description and Major Businesses
Table 109. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Five Prime Therapeutics Product
Table 111. Five Prime Therapeutics Recent Development
Table 112. Fuji Film Kyowa Kirin Biologics Corporation Information
Table 113. Fuji Film Kyowa Kirin Biologics Description and Major Businesses
Table 114. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Fuji Film Kyowa Kirin Biologics Product
Table 116. Fuji Film Kyowa Kirin Biologics Recent Development
Table 117. Genexine Corporation Information
Table 118. Genexine Description and Major Businesses
Table 119. Genexine Cancer Angiogenesis Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Genexine Product
Table 121. Genexine Recent Development
Table 122. Hetero Drugs Corporation Information
Table 123. Hetero Drugs Description and Major Businesses
Table 124. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Hetero Drugs Product
Table 126. Hetero Drugs Recent Development
Table 127. ImClone Systems Corporation Information
Table 128. ImClone Systems Description and Major Businesses
Table 129. ImClone Systems Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. ImClone Systems Product
Table 131. ImClone Systems Recent Development
Table 132. Novartis Corporation Information
Table 133. Novartis Description and Major Businesses
Table 134. Novartis Cancer Angiogenesis Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. Novartis Product
Table 136. Novartis Recent Development
Table 137. Global Cancer Angiogenesis Inhibitors Sales Forecast by Regions (2021-2026) (K Pcs)
Table 138. Global Cancer Angiogenesis Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 139. Global Cancer Angiogenesis Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 140. Global Cancer Angiogenesis Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 141. North America: Cancer Angiogenesis Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 142. North America: Cancer Angiogenesis Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Europe: Cancer Angiogenesis Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 144. Europe: Cancer Angiogenesis Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Asia Pacific: Cancer Angiogenesis Inhibitors Sales Forecast by Region (2021-2026) (K Pcs)
Table 146. Asia Pacific: Cancer Angiogenesis Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 147. Latin America: Cancer Angiogenesis Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 148. Latin America: Cancer Angiogenesis Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Middle East and Africa: Cancer Angiogenesis Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 150. Middle East and Africa: Cancer Angiogenesis Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 151. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 152. Key Challenges
Table 153. Market Risks
Table 154. Main Points Interviewed from Key Cancer Angiogenesis Inhibitors Players
Table 155. Cancer Angiogenesis Inhibitors Customers List
Table 156. Cancer Angiogenesis Inhibitors Distributors List
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Angiogenesis Inhibitors Product Picture
Figure 2. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. VEGF Targeted Therapy Product Picture
Figure 4. FGF Targeted Therapies Product Picture
Figure 5. Oncogene Targeted Therapy Product Picture
Figure 6. Matrix Degrading & Remodeling Targeted Therapy Product Picture
Figure 7. Others Product Picture
Figure 8. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 9. Cancer
Figure 10. Interferon Alpha-2α
Figure 11. Ocular Neovascularization
Figure 12. Cancer Angiogenesis Inhibitors Report Years Considered
Figure 13. Global Cancer Angiogenesis Inhibitors Market Size 2015-2026 (US$ Million)
Figure 14. Global Cancer Angiogenesis Inhibitors Sales 2015-2026 (K Pcs)
Figure 15. Global Cancer Angiogenesis Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2015-2020)
Figure 17. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region in 2019
Figure 18. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2015-2020)
Figure 19. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region in 2019
Figure 20. Global Cancer Angiogenesis Inhibitors Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Cancer Angiogenesis Inhibitors Revenue in 2019
Figure 22. Cancer Angiogenesis Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2015-2020)
Figure 24. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type in 2019
Figure 25. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2015-2020)
Figure 26. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type in 2019
Figure 27. Global Cancer Angiogenesis Inhibitors Market Share by Price Range (2015-2020)
Figure 28. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2015-2020)
Figure 29. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application in 2019
Figure 30. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2015-2020)
Figure 31. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application in 2019
Figure 32. North America Cancer Angiogenesis Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Cancer Angiogenesis Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Cancer Angiogenesis Inhibitors Sales Market Share by Country in 2019
Figure 35. North America Cancer Angiogenesis Inhibitors Revenue Market Share by Country in 2019
Figure 36. U.S. Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Cancer Angiogenesis Inhibitors Market Share by Type in 2019
Figure 41. North America Cancer Angiogenesis Inhibitors Market Share by Application in 2019
Figure 42. Europe Cancer Angiogenesis Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Cancer Angiogenesis Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Country in 2019
Figure 45. Europe Cancer Angiogenesis Inhibitors Revenue Market Share by Country in 2019
Figure 46. Germany Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Cancer Angiogenesis Inhibitors Market Share by Type in 2019
Figure 57. Europe Cancer Angiogenesis Inhibitors Market Share by Application in 2019
Figure 58. Asia Pacific Cancer Angiogenesis Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Cancer Angiogenesis Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Region in 2019
Figure 61. Asia Pacific Cancer Angiogenesis Inhibitors Revenue Market Share by Region in 2019
Figure 62. China Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Cancer Angiogenesis Inhibitors Market Share by Type in 2019
Figure 85. Asia Pacific Cancer Angiogenesis Inhibitors Market Share by Application in 2019
Figure 86. Latin America Cancer Angiogenesis Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Cancer Angiogenesis Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Cancer Angiogenesis Inhibitors Sales Market Share by Country in 2019
Figure 89. Latin America Cancer Angiogenesis Inhibitors Revenue Market Share by Country in 2019
Figure 90. Mexico Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Cancer Angiogenesis Inhibitors Market Share by Type in 2019
Figure 97. Latin America Cancer Angiogenesis Inhibitors Market Share by Application in 2019
Figure 98. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Market Share by Country in 2019
Figure 102. Turkey Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Cancer Angiogenesis Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Cancer Angiogenesis Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Cancer Angiogenesis Inhibitors Market Share by Type in 2019
Figure 109. Middle East and Africa Cancer Angiogenesis Inhibitors Market Share by Application in 2019
Figure 110. North America Cancer Angiogenesis Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Cancer Angiogenesis Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Cancer Angiogenesis Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Cancer Angiogenesis Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Cancer Angiogenesis Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Cancer Angiogenesis Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Cancer Angiogenesis Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Cancer Angiogenesis Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Cancer Angiogenesis Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
血管新生モジュレーターの世界市場（～2026年） Market Analysis and Insights: Global Angiogenesis Modulators Market The global Angiogenesis Modulators market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Angiogenesis Modulators Scope and Market Size Angiogenesis Modulato…- 膵臓がん治療の世界市場（～2026年） Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity …
- 精密がん治療の世界市場（～2026年） Precision cancer therapies is an evolving approach to cancer care that aims to leverage new knowledge regarding the pathogenesis of cancer to more precisely target therapy. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormali…
- 卵巣がん遺伝子治療の世界市場（～2026年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…
- 癌チューブリン阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Tubulin Inhibitors Market The global Cancer Tubulin Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Tubulin Inhibitors Scope and Market Size Cancer Tubulin …